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Abstract
Background: Studies of the immunogenicity of the killed bivalent whole cell oral cholera vaccine, Shanchol, have been
performed in historically cholera-endemic areas of Asia. There is a need to assess the immunogenicity of the vaccine in Haiti
and other populations without historical exposure to Vibrio cholerae.
Methodology/Principal Findings: We measured immune responses after administration of Shanchol, in 25 adults, 51 older
children (6–17 years), and 47 younger children (1–5 years) in Haiti, where cholera was introduced in 2010. A$4-fold increase
in vibriocidal antibody titer against V. cholerae O1 Ogawa was observed in 91% of adults, 74% of older children, and 73% of
younger children after two doses of Shanchol; similar responses were observed against the Inaba serotype. A$2-fold
increase in serum O-antigen specific polysaccharide IgA antibody levels against V. cholerae O1 Ogawa was observed in 59%
of adults, 45% of older children, and 61% of younger children; similar responses were observed against the Inaba serotype.
We compared immune responses in Haitian individuals with age- and blood group-matched individuals from Bangladesh, a
historically cholera-endemic area. The geometric mean vibriocidal titers after the first dose of vaccine were lower in Haitian
than in Bangladeshi vaccinees. However, the mean vibriocidal titers did not differ between the two groups after the second
dose of the vaccine.
Conclusions/Significance: A killed bivalent whole cell oral cholera vaccine, Shanchol, is highly immunogenic in Haitian
adults and children. A two-dose regimen may be important in Haiti, and other populations lacking previous repeated
exposures to V. cholerae.
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Introduction
Cholera remains a public health problem for many of the
world’s poorest individuals. Approximately 3 million cases of
diarrheal illness and 120,000 deaths are caused by V. cholerae
annually [1]. Devastating epidemics occur when V. cholerae is
introduced into an immunologically naive population that lacks
access to safe water and sanitation. This occurred when a
pandemic V. cholerae O1 strain was introduced into Haiti in 2010
[2,3], resulting in 693,088 cases and 8474 reported deaths as of
November 27, 2013 [4]. The increasing burden of endemic and
epidemic cholera has led to recognition that new approaches to
the control of cholera, including vaccination, are urgently needed
[5,6].
There are two currently licensed cholera vaccines. Both are oral
killed whole cell vaccines that have demonstrated efficacy in
preventing cholera in endemic settings. Dukoral (Crucell) is a
whole cell recombinant cholera toxin B subunit vaccine (WC-rBS)
which contains both the Inaba and Ogawa serotypes of V. cholerae
O1, and recombinant cholera toxin B subunit (CTB). Shanchol
(Shantha Biotechnics) is a bivalent whole cell vaccine which
contains V. cholerae serogroups O1 and O139, but lacks CTB.
Shanchol is less expensive than Dukoral and may be associated
with longer lasting protection [7–10].
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cholera vaccines be used in cholera-endemic settings [11].
However, the use of vaccination during epidemics remains
controversial, and in 2010 the WHO position paper on cholera
vaccination encouraged studies of the feasibility and impact of
vaccination in the setting of ongoing outbreaks of cholera [11].
Recent pilot vaccination campaigns in Haiti, South Sudan, and
Guinea have demonstrated the feasibility of reactive and/or
preventive cholera vaccination [12–14]. In a pilot vaccination
campaign in rural Haiti, Shanchol was distributed to 45,417
individuals in conjunction with health education messages
regarding household water safety and sanitation. Despite logistical
challenges in this setting, a vaccination coverage rate in excess of
75% was achieved [12], exceeding the 50% threshold associated
with high levels of herd immunity [15]. Notably, 91% of vaccine
recipients in the pilot campaign in Haiti received the recom-
mended two doses of the vaccine [12].
While the immunogenicity of Shanchol has been demonstrated
in South Asia [8,16], no studies of the immunogenicity of this
vaccine have yet been reported outside of historically cholera-
endemic areas. Prior experience suggests that immunogenicity and
efficacy of cholera vaccines in populations from historically
cholera-endemic areas of Asia may not be extrapolated to
populations from other geographic regions. For instance, a study
conducted in Peru shortly after the introduction of V. cholerae in
1991 demonstrated that a third dose of the WC-rBS vaccine was
required to provide a high rate of seroconversion and boost
protective efficacy from 0% to 61% [17]. In contrast, a two-dose
regimen of a similar vaccine was associated with 86% protection in
Bangladesh [18].
In this study, we address a knowledge gap regarding the use of
Shanchol in epidemic settings. To assess the immunogenicity of
this vaccine in Haiti, we measured vibriocidal antibody responses,
the best characterized immunologic correlate of protection
against cholera [19,20]. We also assessed IgA responses to the
O-antigen specific polysaccharide (OSP), the primary determi-
nant of lipopolysaccharide antigen specificity [21]. We included
young children in our analysis, since they are disproportionately
affected by cholera [22] and may mount less robust immune
responses to cholera vaccination [7,23,24]. We also included a
comparison of immune responses of Haitian vaccinees to
Bangladeshi vaccinees to assess whether immune responses to
Shanchol would differ in individuals from a historically cholera-
endemic area compared to an area where cholera has recently
been introduced.
Methods
Enrollment of study participants
Subjects were enrolled in St. Marc, Haiti, in April 2013.
Subjects 1 year of age and older were eligible to participate.
Exclusion criteria included pregnancy, acute medical illness, prior
receipt of oral cholera vaccine, or a history of hospitalization for
cholera. We also analyzed plasma samples obtained from
Bangladeshi individuals who participated in a previously conduct-
ed study of the immunogenicity of Shanchol in Bangladesh [16].
The Bangladeshi individuals whose samples were utilized were
selected at random from a larger cohort of vaccinees and then age-
matched to Haitian vaccinees to within 1 year for young children
and within 5 year for adults and blood-group matched for either O
or non-O blood groups.
Ethics statement
The studies were approved by the institutional review board of
Partners HealthCare (Brigham and Women’s Hospital and
Massachusetts General Hospital), the Haitian National Ethics
Committee, and the Ethical Review Committee of the Interna-
tional Centre for Diarrhoeal Disease Research in Dhaka,
Bangladesh (icddr,b). Written informed consent was obtained
from adult participants and from guardians of children.
Immunization
Participants were administered two doses of Shanchol, given 14
days apart. Participants were monitored for 30 minutes after
vaccination and were asked to return to the study site or to contact
a study coordinator if they felt ill after receipt of the vaccine.
Adverse events were evaluated and recorded by study physicians.
Samples
Venous blood samples were obtained immediately prior to
immunization (day 0) and seven days after each dose of
vaccination (day 7 and day 21). Serum was stored at 280uC,
and shipped to Massachusetts General Hospital. To avoid any
laboratory-related biases, plasma from Bangladesh from a
previously conducted study of the immunogenicity of Shanchol
vaccine was stored, shipped, and analyzed at Massachusetts
General Hospital concurrently with the Haitian samples [16].
Immunologic assays
Vibriocidal antibody assays were performed as described
previously [16,25]. Target strains of V. cholerae O1 Inaba
(T19479) and Ogawa (X25049), were incubated with heat
inactivated serum and exogenous guinea pig complement.
Vibriocidal titers were defined as the reciprocal of the highest
serum dilution resulting in a 50% reduction in optical density
(595 nm) compared to controls without serum. To account for
inter-assay variation, results were normalized using high titer sera.
Seroconversion was defined as a 4-fold or greater increase from
the baseline vibriocidal titer after vaccination.
CTB and OSP responses were measured using a previously
described ELISA [23,26]. OSP plates were coated with 1 mgo f
conjugated OSP:BSA per milliliter of carbonate buffer (pH 9.6).
CTB plates were coated with GM1 ganglioside followed by
recombinant CTB (2.5 mg/ml). Sera (diluted 1:25 for OSP, 1:50
for CTB) was added to plates, and IgA responses were detected
with goat anti-human IgA conjugated with horseradish peroxidase
(Jackson ImmunoResearch). A 2-fold or greater rise in milli-
absorbance units per second at day 7 or day 21 compared to day 0
was considered a significant response. Because Shanchol does not
contain CTB, these responses were assessed to ensure that
Author Summary
Studies evaluating the ability of the killed bivalent whole
cell oral cholera vaccine, Shanchol, to elicit an immune
response have been performed in historically cholera-
endemic areas of Asia. There is a need to assess whether
the vaccine is able to elicit an immune response in Haiti
and other populations without historical exposure to
cholera. In this study, we measure immune responses after
administration of Shanchol, in 25 adults, 51 older children
(6–17 years), and 47 younger children (1–5 years) in Haiti,
where cholera was introduced in 2010. A killed bivalent
whole cell oral cholera vaccine (Shanchol) is capable of
inducing an immune response in adults and children living
in Haiti. However, a two-dose regimen may be important
in Haiti and other populations lacking historical exposure
to cholera.
Immune Responses to Shanchol
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natural V. cholerae infection or non-specific immune activation.
Statistical analysis
Statistical analyses were performed using STATA Version 9.
Antibody titers were log2 transformed, and the log-transformed
data were used for statistical analyses. The immunologic results
were expressed as geometric means (GMT) and compared by a
paired t-test for within group comparison and by the Kruskal-
Wallis analysis of variance (ANOVA) and/or Student’s t-test for
between group comparisons as indicated. Analysis of proportions
was performed using chi-square or the Fisher exact test as
appropriate. For the matched comparison between the Haitian
and Bangladeshi cohorts, subjects were matched by age (within
one year for all children, and within 5 years for adults) and blood
group; the differences between GMT were assessed using a paired
t-test. The threshold for statistical significance was a two-tailed p
value of ,0.05.
Results
Study enrollment and participation
The study cohort consisted of 123 Haitian participants (Table 1),
of whom 25 were adults ($18 years), 51 were older children (6–17
years), and 47 were younger children (1–5 years).
A flowchart of participants through the study is provided in
Figure 1. Of the 123 participants, 115 (93%) received both doses of
the vaccine. No adverse events related to vaccination were
reported among participants.
Vibriocidal antibody responses
Figure 2 shows the vibriocidal antibody responses. The baseline
GMT to V. cholerae O1 Ogawa was 14, 21, and 14 for adults, older
children, and young children, respectively; and for Inaba the
baseline GMT was 11, 27, and 16 for each age cohort. There was
a statistically significant difference in baseline GMT between
adults and older children (p=0.02) to V. cholerae O1 Inaba, but
there was no difference in baseline GMT among age cohorts for
Ogawa. Overall, 34% of participants had a baseline vibriocidal
titer $80 to Ogawa and/or Inaba; 14% of participants had a
GMT $320 and 7% of participants had a GMT $640. This
suggests that many individuals had been recently exposed to V.
cholerae. However, the proportion of individuals with a baseline
vibriocidal titer $80 did not differ significantly between age
cohorts.
Each of the age cohorts had a robust vibriocidal antibody
response by day 7, after a single dose of Shanchol (p,0.0001 for
all cohorts) with a geometric mean fold rise (GMF) of 11, 9, and 11
in adults, older children, and young children to V. cholerae O1
Ogawa, and 19, 11, and 9 to Inaba. Vibriocidal GMTs increased
further in each of the age cohorts after the second dose of the
vaccine. Although these increases between day 7 and day 21 were
not statistically, significant, the GMT at day 21 was significantly
increased compared to baseline values in all age cohorts (Ogawa
GMF: 13, 9, 12 and Inaba GMF: 19, 10, 10 for adults, older
children, and young children) (p,0.0001).
The majority of adults, older and younger children demon-
strated vibriocidal antibody seroconversion against both serotypes
(Table 2). Approximately half of the individuals who failed to
seroconvert after vaccination had high baseline titers suggestive of
recent exposure. Of the 22 vaccinees who did not seroconvert to
Ogawa, 15 (68%) had a baseline vibriocidal titer of $80, and of
the 15 vaccinees who did not seroconvert to Inaba, 8 (53%) had a
baseline titer $80.
V. cholerae-specific serum antibody responses
Vaccinees across all age groups developed significant OSP-
specific IgA serum responses at day 7 and day 21 (Figure 3). Rates
of seroconversion, as defined as a 2-fold rise in antibody level, were
comparable across age groups for OSP of Ogawa and Inaba
(Table 2). We also evaluated CTB IgG and IgA serum responses
on a subset of patients. As expected, there was no increase in CTB
responses after immunization (data not shown).
Children younger than 2 years
Because children younger than two years have diminished
responses to T-cell independent vaccine antigens, we compared
children younger than 2 years of age (N=8) with children between
2 and 5 years (N=35). The very young children (,2 years) had a
lower vibriocidal GMT on day 7 compared to the 2–5 years old
children (Ogawa GMT 40 vs. 177, p=0.07; Inaba GMT 20 vs
184, p=0.02). However, after two doses of the vaccine there was
no statistically significant difference in the vibriocidal GMT
between 1 year olds and 2–5 year olds (Ogawa GMT 226 vs 183
p=0.76; Inaba GMT 80 vs. 200 p=0.26).
Relationship of blood group with post-vaccination titers
Overall, 63 individuals were blood type O (51.2%). Individuals
with blood type O had a greater vibriocidal GMT against serotype
Inaba after two doses of vaccine compared to study participants
with non-O blood types (GMT=300 for group O, GMT=160 for
non-O p=0.02), but there was no significant difference in the
vibriocidal response to the Ogawa serotype (Figure 4). There were
no significant differences in magnitude in OSP-specific IgA
responses between blood groups (data not shown).
Comparison of immune responses in Haitian and
Bangladeshi vaccinees
We compared immune responses in a subset of Haitian
vaccinees with age- and blood group-matched vaccinees from
Bangladesh (Figure 5). The cohort from Bangladesh consisted of
Table 1. Demographic characteristics of Haitian study participants.
Characteristics Total Adults ($18 yo) Older children (6–17 yo) Young Children (1–5 yo)
N=123 N=25 N=51 N=47
Mean Age, years (S.D.)* 16.6 (15) 32.7 (11) 11.3 (4) 3.1 (1)
Percent Female 63 80 61 55
Percent Blood Type O 51 44 59 47
*standard deviation.
doi:10.1371/journal.pntd.0002828.t001
Immune Responses to Shanchol
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the young children in the matched cohorts were younger than 2
years old, which skewed the pool of young children in the matched
analysis toward a younger average age (2.3 years in the matched
cohort, 3.1 years in the larger Haitian cohort).
Even though cholera has been endemic in Bangladesh, and only
recently introduced in Haiti, the baseline GMT vibriocidal
antibody titers and proportion of individuals with baseline
vibriocidal titers $80 were comparable between the two matched
cohorts.
Among the matched cohorts, the adult Bangladeshi vaccine
recipients had higher vibriocidal GMT after the first dose of
vaccine compared to adult Haitian vaccinees (Figure 5A and 5B).
This was statistically significant for the Inaba serotype (Inaba
GMT in Haitians =153 and Bangladeshis =351, p=0.03).
However, this difference was diminished and no longer significant
after a second dose of the vaccine (Inaba GMT for Haitians =153
and Bangladeshis =243, p=0.20).
The difference between matched cohorts at day 7 was more
pronounced for young children (Figure 5C and 5D). The
vibriocidal GMT to V. cholerae O1 Ogawa at day 7 was 63 for
Haitian young children compared to 443 for Bangladeshi young
children (p=0.002); and 40 for Haitians and 465 for Bangladeshi
to V. cholerae O1 Inaba (p=0.004). Again, the differences are
diminished and no longer statistically significant after a second
dose of vaccine (Ogawa GMT in Haitian young children =209
and Bangladeshi young children =303, p=0.57; Inaba GMT for
Haitians =160 and Bangladeshis =435, p =0.31).
Figure 1. Enrollment and follow-up of study participants.
doi:10.1371/journal.pntd.0002828.g001
Immune Responses to Shanchol
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To our knowledge, this is the first report of the immunogenicity
of the killed bivalent whole cell cholera vaccine, Shanchol, outside
of historically cholera-endemic areas of Asia. We found that
Shanchol was immunogenic across all age groups in Haiti, from
adults to very young children. Given the ongoing transmission of
V. cholerae O1 in Haiti, these findings provide additional evidence
to suggest that expansion of cholera vaccination programs would
aid cholera control efforts in Haiti.
The results of this study are notable because V. cholerae was only
recently introduced in Haiti. Previous studies of the immunoge-
nicity and efficacy of Shanchol have been conducted in the
historically cholera-endemic Ganges delta area of South Asia [7–
10,16]. Because levels of previous or repeated exposures to V.
cholerae may dictate the magnitude of vaccine responses, it was
unclear whether similar immune responses would be seen in the
Haitian population. In addition, recent evidence suggests that
genetic factors influencing the innate immune response to V.
cholerae may differ in individuals of Bengali ethnic heritage,
providing another possible reason for differing immune response
to cholera vaccines between different populations [27].
In fact, the results of our direct age- and blood group- matched
comparisons suggest the immunogenicity of Shanchol is compa-
rable in Bangladesh and Haiti, at least when administered in a
two-dose regimen. Vibriocidal antibody titers are considered an
important marker for assessing the immunologic response to
cholera vaccines [28,29], and we found the proportion of Haitian
vaccinees who demonstrated vibriocidal seroconversion ap-
proached or exceeded 75% across all age cohorts. This compares
favorably with the seroconversion rates seen in Bangladeshi
vaccinees [16]. In addition, the final magnitude of the vibriocidal
antibody response after two doses of the vaccine was comparable
in Haitian and Bangladeshi individuals.
The major difference between the Bangladeshi and Haitian
study populations were that immune responses were of a greater
magnitude after the first dose of Shanchol among Bangladeshis.
We believe this difference is most likely explained by a higher level
of immunologic priming from previous or repeated exposure to V.
cholerae in the Bangladeshi vaccinees. The observation that baseline
vibriocidal titers were similar in both groups seems counter to this
hypothesis, but we and others have previously shown that
vibriocidal antibodies are a relatively short-term immunologic
marker of past-exposure [25,30]. Thus it is possible, that longer
lasting memory B cell responses following natural V. cholerae
infection may mediate anamnestic responses to vaccines in
historically cholera-endemic areas. An alternative possibility is
that this difference is due to other genetic or environmental
differences, though this seems less plausible as the differences are
mitigated (rather than accentuated) by a second dose of the
vaccine. Regardless, our findings suggest that the efficacy of single
dose oral cholera vaccine may differ in an epidemic versus a
historically cholera-endemic setting.
This report also includes the first analysis of O-specific
polysaccharide responses to V. cholerae outside of Asia. The
vibriocidal response is largely thought to be comprised of IgM
targeting V. cholerae lipopolysaccharide (LPS) [31,32]. Protective
immunity against V. cholerae is serogroup-specific, and serogroup
specificity is defined by OSP. OSP is a T cell independent antigen,
and young children are not typically able to mount immune
Figure 2. Vibriocidal responses. Geometric mean titer (+SEM) of vibriocidal responses to V. cholerae O1 Ogawa (A) and Inaba (B) by age group at
baseline (day 0) and 7 days after each immunization (day 7 and day 21). Statistically significant differences relative to baseline are indicated (** = ,
0.001).
doi:10.1371/journal.pntd.0002828.g002
Table 2. Seroconversion rates among Haitians receiving two doses of Shanchol.*
Adults ($18 yo) Older children (6–17 yo) Young Children (1–5 yo)
N=22 N=42 N=33
Vibriocidal (Ogawa) 91% 74% 73%
Vibriocidal (Inaba) 91% 86% 79%
OSP IgA (Ogawa) 59% 45% 61%
OSP IgA (Inaba) 50% 55% 55%
*vibriocidal $4-fold increase, OSP (O-Specific Polysaccharide) $2-fold increase in kinetic ELISA.
doi:10.1371/journal.pntd.0002828.t002
Immune Responses to Shanchol
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a cholera epidemic among an immunologically-naı ¨ve population,
cholera afflicts children and adults equally, and in endemic
populations, children bear a large burden of cholera. In our
analysis, however, we found that young children were able to
mount serum IgA OSP responses that were comparable to those
induced in older children and adults. This is in contrast to serum
IgA OSP responses observed with administration of Dukoral to
children in Bangladesh where only children over the age of 5 had
a significant OSP response to Dukoral [23]. This difference may
be due to the lower concentration of LPS present in Dukoral
compared to Shanchol, or due to the immunodulatory effects of
CTB present in Dukoral vaccine [33]. Interestingly, despite the
observation that a second dose of Shanchol boosted vibriocidal
responses, no additional boosting of OSP serum IgA responses
was observed following a second dose in younger and older
Haitian children. The significance of these observations is
uncertain.
The ABO blood group has been implicated in the susceptibility
and severity of cholera [34–36], as well as the immunogenicity and
efficacy of oral cholera vaccines, with higher responses and efficacy
generally seen in the blood group O population which is at greater
risk of severe cholera [37,38]. Our study also showed increased
vibriocidal antibody responses to Shanchol in blood group O
individuals, although this was only seen for Inaba serotype after
two doses of the vaccine.
There are some important limitations of our study. While the
vibriocidal antibody response is the historical immunologic
benchmark for cholera vaccines [28], it is at best an indirect
marker of protection as the protection afforded by cholera
vaccines outlasts a measurable vibriocidal response by several
years [39]. Thus, while immunologic results from our study
support the expansion of vaccination efforts, epidemiologic data
on vaccine efficacy is still important. In addition, our study design
was not a placebo-controlled trial of Shanchol since such as design
would not be acceptable in an epidemic setting. However, we
believe our immunologic results clearly demonstrate vaccine-
specific responses, given the rise in both vibriocidal and OSP-IgA
antibodies without concurrent reactivity to CTB, which is not
present in the Shanchol vaccine.
In summary, we demonstrated that Haitian adults and children
had robust immune responses to the killed whole cell bivalent oral
cholera vaccine Shanchol. This provides evidence that the vaccine
is immunogenic even in areas where cholera has recently been
introduced, and contributes to the body of evidence favoring the
use of oral cholera vaccines as a component of comprehensive
cholera control in epidemic settings in immunologically naı ¨ve
populations.
Figure 3. OSP-specific IgA responses. OSP-specific IgA responses to V. cholerae O1 Ogawa (A) and Inaba (B) by age group at baseline (day 0) and
7 days after each immunization (day 7 and day 21). Statistically significant differences relative to baseline are indicated (** = ,0.001).
doi:10.1371/journal.pntd.0002828.g003
Figure 4. Vibriocidal responses in O and Non-O blood groups. Geometric mean titer (+SEM) of vibriocidal responses to V. cholerae O1 Ogawa
(A) and Inaba (B) by blood group at baseline (day 0) and 7 days after each immunization (day 7 and day 21). Statistically significant differences across
blood groups are indicated (* = ,0.05).
doi:10.1371/journal.pntd.0002828.g004
Immune Responses to Shanchol
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